SCHEMBL1304433

SCHEMBL1304433

CC(=O)N1C(=O)/C(=C/c2ccc(/C=C3/C(=O)Nc4cc(C(=O)O)ccc43)o2)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.52
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 4/20 0.45
POLB P06746 4/20 0.45
KMT2A Q03164 4/20 0.45
DYRK1A Q13627 1/20 0.45
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
ALOX12 P18054 1/20 0.45
PTPN1 P18031 7/20 0.44
PPM1G O15355 1/20 0.44
PTPN7 P35236 1/20 0.44
PTPN5 P54829 1/20 0.44
PTPRO Q16827 1/20 0.44
PTPN22 Q9Y2R2 1/20 0.44
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CTDSP1 Q9GZU7 2/20 0.42
APEX1 P27695 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304434 1.00 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304861 0.99 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304858 0.99 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL3130082 0.93 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL3130088 0.93 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304354 0.92 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304351 0.92 PIM1 (0.52) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304859 0.91 ALDH1A1 (0.43) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304521 0.88 ALDH1A1 (0.58) PIM1ALDH1A1MEN1POLBKMT2A
SCHEMBL1304522 0.88 ALDH1A1 (0.58) PIM1ALDH1A1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053461-B2 Oxindole derivative THERAVALUES CORPORATION (JP) 2011-11-08 US disclosed
US-8053461-B2 Oxindole derivative THERAVALUES CORPORATION (JP) 2011-11-08 US disclosed
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE THERAVALUES CORPORATION (JP) 2010-03-25 US disclosed
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE THERAVALUES CORPORATION (JP) 2010-03-25 US disclosed
EP-2130829-A1 NOVEL HYDROXYINDOLE DERIVATIVE Theravalues Corporation (JP) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE CYP2C9, HDAC10, SIGMAR1 PIM1 4561/4885ALDH1A1 957/4885MEN1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.